.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

BREVIBLOC Drug Profile

« Back to Dashboard
Brevibloc is a drug marketed by Baxter Hlthcare and is included in one NDA. It is available from five suppliers. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has thirty-two patent family members in twenty-four countries.

The generic ingredient in BREVIBLOC is esmolol hydrochloride. There are eight drug master file entries for this compound. Ten suppliers are listed for this compound. There is one tentative approval for this compound. Additional details are available on the esmolol hydrochloride profile page.

Summary for Tradename: BREVIBLOC

Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: see list5
Drug Prices: :see details

Pharmacology for Tradename: BREVIBLOC

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Baxter Hlthcare
BREVIBLOC
esmolol hydrochloride
INJECTABLE;INJECTION019386-003Aug 15, 1988DISCNNo► subscribe► subscribe
Baxter Hlthcare
BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER
esmolol hydrochloride
INJECTABLE;INJECTION019386-005Jan 27, 2003RXYes6,528,540*PED► subscribeY► subscribe
Baxter Hlthcare
BREVIBLOC
esmolol hydrochloride
INJECTABLE;INJECTION019386-007May 28, 2003DISCNNo6,310,094*PED► subscribeY► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: BREVIBLOC

These historical archives are available as an add-on to one-year subscriptions.
See the Subscription Options for more information.

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Baxter Hlthcare
BREVIBLOC
esmolol hydrochloride
INJECTABLE;INJECTION019386-003Aug 15, 19884,387,103► subscribe
Baxter Hlthcare
BREVIBLOC
esmolol hydrochloride
INJECTABLE;INJECTION019386-006Feb 25, 20034,593,119*PED► subscribe
Baxter Hlthcare
BREVIBLOC
esmolol hydrochloride
INJECTABLE;INJECTION019386-003Aug 15, 19884,593,119*PED► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: BREVIBLOC

Drugname Dosage Strength RLD Submissiondate
esmolol hydrochlorideInjection10 mg/mL, 250 mL infusion bags and 20 mg/mL, 100 mL infusion bagsBrevibloc1/31/2014

International Patent Family for Tradename: BREVIBLOC

Country Document Number Estimated Expiration
Poland216192► subscribe
Slovakia12782002► subscribe
South Africa200206688► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc